Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1988 1
1989 1
1991 1
1992 2
1993 1
1994 1
1995 1
1999 1
2002 1
2003 3
2004 1
2005 4
2006 5
2007 5
2008 8
2009 6
2010 5
2011 6
2012 8
2013 12
2014 12
2015 10
2016 26
2017 20
2018 17
2019 15
2020 11
2021 22
2022 16
2023 6
2024 7
2025 9
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

224 results

Results by year

Filters applied: . Clear all
Page 1
Whole-genome doubling drives immune evasion by silencing antigen presentation.
Foidart P, Li Z, Cai X, Seehawer M, Brown DD, Tawawalla A, Baldominos P, Parvin S, Nishida J, Rojas-Jimenez E, Bui TM, Diciaccio B, Kumar R, Schlegel BT, Goyette MA, Scales T, Yan P, Qiu X, Li R, Jiang Y, Xie Y, Aarabi M, Huang XY, Stevens LE, Cejas P, Mangiante L, Sotomayor Vivas CI, Houlahan KE, Curtis C, Oesterreich S, Harris IS, Letai AG, Lee AV, Long HW, Agudo J, Polyak K. Foidart P, et al. Among authors: letai ag. Cancer Cell. 2026 May 7:S1535-6108(26)00218-7. doi: 10.1016/j.ccell.2026.04.007. Online ahead of print. Cancer Cell. 2026. PMID: 42102810 Free article.
What does BCL-2 do? From new molecular insights to the clinical implications.
Croce CM, Tait SWG, Garcia-Sáez AJ, Villunger A, Letai A, Walter HS, Dyer MJS, Green DR, Shi Y, Melino G. Croce CM, et al. Among authors: letai a. Cell Death Differ. 2026 Apr;33(4):673-693. doi: 10.1038/s41418-025-01607-3. Epub 2026 Feb 19. Cell Death Differ. 2026. PMID: 41714805 Review.
Drug-tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms.
Davern M, Turner CJ, Griffin D, Bencsics L, Chan BC, Kung JY, Olson ML, Walker Williams C, Soni S, Krotee L, Yorsz M, Antonellis G, Lizotte PH, Paweletz CP, Ryan J, Birocchi F, Almazan AJ, Sarosiek KA, Barbie D, Bhola P, Maus MV, Letai A. Davern M, et al. Among authors: letai a. Cell Death Differ. 2025 Dec 26. doi: 10.1038/s41418-025-01656-8. Online ahead of print. Cell Death Differ. 2025. PMID: 41454172
Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor-risk MDS/AML.
Garcia JS, Kim HT, Murdock HM, Bosch-Vilaseca A, Panaro KM, Lim F, Fiorilla J, Auriemma E, Brock J, Gooptu M, Ho VT, Cutler CS, Shapiro R, Kelkar AH, Abel GA, DeAngelo DJ, Stone RM, Bat-Erdene D, Ryan J, Fell G, Letai A, Ritz J, Lindsley RC, Antin JH, Soiffer RJ. Garcia JS, et al. Among authors: letai a. Blood Adv. 2026 Mar 10;10(5):1548-1558. doi: 10.1182/bloodadvances.2025018631. Blood Adv. 2026. PMID: 41348911 Free PMC article. Clinical Trial.
Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemia.
Minihane EJ, Krotee L, Wu J, Thornton L, Fell G, Herter S, Ryan J, Jakkani A, Marinchev K, Lane AA, Luskin MR, Winer ES, Chen EC, Shimony S, Wadleigh M, Vedula R, Volpe VO, Reilly C, Galinsky I, DeAngelo DJ, Stone RM, Neuberg DS, Letai A, Garcia JS. Minihane EJ, et al. Among authors: letai a. bioRxiv [Preprint]. 2025 Oct 15:2025.10.14.682414. doi: 10.1101/2025.10.14.682414. bioRxiv. 2025. PMID: 41278625 Free PMC article. Preprint.
TP53 mutations drive therapy resistance via post-mitochondrial caspase blockade.
Mamdouh AM, Olesinski EA, Lim FQ, Jasdanwala S, Mi Y, Lin NSE, Liang DTE, Chitkara N, Hogdal L, Lindsley RC, Letai A, Itahana K, Bhatt S. Mamdouh AM, et al. Among authors: letai a. bioRxiv [Preprint]. 2025 Aug 31:2025.08.28.672283. doi: 10.1101/2025.08.28.672283. bioRxiv. 2025. PMID: 40909637 Free PMC article. Preprint.
Combining MCL-1 inhibition and CD37-directed chimeric antigen receptor T cells as an effective strategy to target T-cell lymphoma.
Heavican-Foral TB, Korell F, Scarfò I, Wiggers CRM, B AT, Eisenbies Z, Powers F, Hegel J, Liu J, Kulp S, Silva H, Wu G, Letai A, Stegmaier K, Lohr JG, Weinstock DM, Maus MV, Knoechel B. Heavican-Foral TB, et al. Among authors: letai a. Leukemia. 2025 Oct;39(10):2452-2464. doi: 10.1038/s41375-025-02697-1. Epub 2025 Jul 30. Leukemia. 2025. PMID: 40739330 Free PMC article.
Targetable BIRC5 dependency in therapy-resistant TP53 mutated acute myeloid leukemia.
Mamdouh AM, Lim FQ, Mi Y, Olesinski EA, Chan CGT, Jasdanwala S, Lin XX, Wang Y, Tan JYM, Bhatia KS, Sapozhnikova V, Wang C, Mahesh AN, Liang DTE, Chitkara N, Mertins P, Hogdal L, Brown BD, Haferlach T, Lobry C, Lindsley C, Puissant A, Ho HK, Das S, Letai A, Kornblau SM, Krönke J, Ayoub E, Itahana K, Andreeff M, Bhatt S. Mamdouh AM, et al. Among authors: letai a. bioRxiv [Preprint]. 2025 May 22:2025.05.17.654633. doi: 10.1101/2025.05.17.654633. bioRxiv. 2025. PMID: 40475516 Free PMC article. Preprint.
224 results